Open Access Open Access  Restricted Access Subscription or Fee Access

In-Vitro and In-Vivo Anti-Adipogenecity Activity of Two Plants using Rat Models

Sandeep Kaur Saggi

Abstract


This study examines how extracts of plant affect the dyslipidaemic state of fatty acid induced rats. Eight days following induction for differentiation with C-DMEM and simultaneously tested with the extracts of plant (day 8), our study found significantly reduced (p < 0.05) intracellular lipid accumulations in white muscle cells in the rats. This compared positively against the smaller reduction in accumulation found in the standard drug streptozotosin (STZ). This suppressing effect was found to be dose-dependent. Additionally, cytotoxicity assay demonstrate the toxicity of different extracts in 3T3-L1 cell lines at different concentration. These results suggest that the different extracts of herbal plant has significant reduction in lipid droplet accumulations and these cell line has more than 75% cell viability. Further studies recommended exploring the potential health benefits of plants in the control of obesity and type 2 diabetes.This study examines how extracts of plant affect the dyslipidaemic state of fatty acid induced rats. Eight days following induction for differentiation with C-DMEM and simultaneously tested with the extracts of plant (day 8), our study found significantly reduced (p < 0.05) intracellular lipid accumulations in white muscle cells in the rats. This compared positively against the smaller reduction in accumulation found in the standard drug streptozotosin (STZ). This suppressing effect was found to be dose-dependent. Additionally, cytotoxicity assay demonstrate the toxicity of different extracts in 3T3-L1 cell lines at different concentration. These results suggest that the different extracts of herbal plant has significant reduction in lipid droplet accumulations and these cell line has more than 75% cell viability. Further studies recommended exploring the potential health benefits of plants in the control of obesity and type 2 diabetes.

Keywords


herbal extract, rat model, adipocytes, dyslipidaemic, anti-adipogenecity.

Full Text:

PDF

References


Assmann, G. (1979) Lipiddiagnostikheute. page 29ff.in Greten. H., et al lipoproteine and Herzinfarkt. Witzstrock. Verlag, Baden-Baden/W. Germany

Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–81.

Ginsberg HN, Goldberg IJ. Disorders of lipoprotein metabolism. In: Braunwald E, Fauci AS, Kasper DL, et al, Internal Medicine. 15th ed. New York, NY: McGraw-Hill Inc; 2001:2245–57

Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 2002;162:1568–76.

Guyton AC, Hall JE. Lipid metabolism. In: Textbook of MedicalPhysiology.10thed.Philadelphia,PA:WBSaunders Company;2000:781-90

Henry, J.B., Clinical Diagnosis& management by Laboratory methods, 18th ed., W.B. Saunders, Philadelphia,1991,p.204-211.

J.P. Jani, S. Specht, N. Stemmler, K. Blanock, S.V. Singh, V. Gupta, A. Katoh, Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis, Invasion Metastasis 13 (1993) 314–324.

Lopes-Virella MF, stone p, Ellis S, Colwell JA. Cholesterol determination in HDL separated by three different methods. Clin Chem1977; 23. 882-4

McKenney JM. Dyslipidemias. In: Koda-Kimble MA, Young LY, Kradjan WA, et al, eds. Applied Therapeutics: The Clinical Use of Drugs. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:chap 11

National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health; May2001.

R. Hampton, D. Dimster-Denk, J. Rine, The biology of HMG-CoA reductase: the pros of contra-regulation, Trends Biochem. Sci. 21 (1996) 140–145

Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease; the Scandinavian Simvastain survival study (45) Lancet 1994;244;1383-9

Rifai N, Bachorik PS, Albers JJ. Lipids, lipoproteins & Apo-lipoproteins. In Burtis CA, Ashood ER, editors. Tiez Textbook of Clincal Chemistry.3rded. Philadelphia; WB Saunders, company;1999. p. 809-61

Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med.1999;341:410–8.

Sack FM, Pfeffer MA, Moye LA, Rouleau Jl, Ruthertford JC, cole TG, et al, The effect of pravasatin on coronary events after MI in patient with average cholesterol levels. New England journal of Medicine 1996;335;1001-9

The lipid Study group, prevention of cardiovascular events and death with paravastain in patients with coronary heart disease and a broad range of initial cholesterol levels. New England journal of medicine 1998; 339; 1349-57

The Long-Term Intervention with Pravastatin in Ischaemic Disease(LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349–57.

M, Arumugam; P, Vijayan; C, Raghu; G, Ashok; SA, Dhanaraj; and CT, Kumarappan (2008) "Anti-Adipogenic Activity of Capsicum annum (Solanaceae) in 3T3 L1," Journal of Complementary and Integrative Medicine: Vol. 5: Iss. 1, Article 28.)




DOI: https://doi.org/10.37628/ijaba.v6i1.578

Refbacks

  • There are currently no refbacks.